RxDoctor Payments Data

Bruce Hough, MD

Hematology & Oncology · Richmond, VANPI 1205887270

Payments from drug & device makers

$127,348in general payments, 2019–2025

Across 25 payments — averaging $5093.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$60K
  • Beone Medicines Ltd.$34K
  • Beone Medicines USA, Inc.$31K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Adaptive Biotechnologies Corporation$381
  • Takeda Pharmaceuticals U.S.A., Inc.$117
  • plus $487 from 12 others

What the payments were for

  • Consulting fees$1,48260%
  • Food & beverage$97339%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,348 in reported general payments places this provider in the 75th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$42,059
Medicare patients
106
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide34$623,030
BrukinsaZanubrutinib45$622,622
PomalystPomalidomide16$363,060
ImbruvicaIbrutinib16$199,914
EliquisApixaban26$15,619
Acyclovir40$1,134
Ondansetron Hcl36$637
Dexamethasone22$332
Prednisone40$74
Potassium Chloride12$57
Allopurinol14$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$12$623,03034 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,482$363,06016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 293 hematology & oncology providers in Virginia.

Other hematology & oncology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →